Excelsior Biopharma Receivables

The latest receivables for 6496.TWO is $190M as of June 2026. That compares with $170M in the prior-year period — up 13.1% year over year. Investors often review this figure alongside Excelsior Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6496.TWO's receivables moved from $170M to $190M — a 13.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Excelsior Biopharma's operating scale or balance-sheet position.

A receivables figure of $190M for 6496.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6496.TWO's receivables ($190M), review year-over-year change from $170M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.